BIT - Biotron Limited

[barney]

$27mn if you include chi-x (which you should)

Yes 100% correct ….. I often forget about the other guy in the room …. Todays Commsec only trading was +$49 million ….. huge for a Spec

 

[debtfree]

A bit of interest in BIT lately so I have chosen it for the August Competition. How it will go for the month only time will tell. Just a chart pick.

My short term MAs have moved above my Longer term MAs, that's a start. Volume dropped when price did of late.
My 1st target for this one is .15 cents (+60%) then next, a big .24 cents (158%)
All or nothing most likely.

 

[debtfree]

I'm taking BIT again in this month's competition. It didn't work out too well last month for me but I thought I'd give it another chance.
Volatility has pulled back so it might be ready to make a move soon, hopefully it will be up.

 

[Dona Ferentes]

Biotron said it has 30 compounds with good activity against a range of coronaviruses, “including human coronaviruses that cause mild cold-like symptoms as well as the SARS coronavirus that was responsible for the outbreak of that virus in 2003”.

“Those compounds can reduce the levels of coranvirus by 90 per cent to 100 per cent in infected cell cultures. "Importantly, several compounds have broad-spectrum activity against multiple strains of coronaviruses.”

Biotron said it was testing a few select compounds against the Wuhan coranvirus, known as 20190-nCoV. The work would be done under contract in specialist laboratories that have access to the new virus, which the company said has only recently been isolated and made available for study.

“Biotron’s priority will be testing its compounds that have shown broad-spectrum activity against different coronaviruses,” Biotron said in a statement to the ASX.

 

[Dona Ferentes]

but tempering the talk

Biotron CEO Michelle Miller says while the company’s work on pan respiratory viruses continues, there’s not much to add at this stage.

“We have some good advanced compounds we can progress towards a treatment,” she says. “They might not work on this current virus but if it hangs around … we would like to be in a position to have something ready to go.”

She says while a vaccine can be developed reasonably quickly, a drug cannot: “even if we have a compound which is absolutely fabulous we would have years of lead time before anything gets to market.”

By that time, the virus will have taken on another malevolent form.

 

[debtfree]

I had a crack at BIT in the Monthly Competition a couple of times last year and I think I'll give it another try for the March Comp.

Plenty of momentum late January, early February but has quieten down last 2-3 weeks with lighter volume. Has held up pretty well while the overall market has dropped away.
ST above LT EMAs and price is sitting nicely just above the 10 day MA. Time will tell as usual.
If it can get back to 17 cents by the end of the month it will be a nice return, roughly 40%.

 

[Purple XS2]

BioTron's announcement 2011-11-25 headlined:
BioTrons' Drug effective against COVID-19 in animals.

Tells us that " ...The Directors of Biotron Limited (ASX: BIT) are pleased to announce that the Company’s lead
clinical asset, BIT225, has demonstrated substantial and clinically meaningful efficacy against
SARS-CoV-2 in a series of animal and cell-based studies performed at The SCRIPPS Research
Institute, La Jolla, CA, USA."

Be interesting to see if the fizz lasts.
And while I'm sure they're more interested in human treatment, they could always take the lower road - if the 'Rona turns into a major problem for livestock?

Discl: I don't hold.

 

[Boggo]

It's defying the rest of the market today. The expected news coming ?? (I do hold).

(click to expand)

 

[debtfree]

Biotron (ASX:BIT) from Stockhead

Up 185% since 25th September's Close.

Biotron shares spiked in the last week of September, and the company was promptly issued a speeding ticket by the ASX.
This follows a Tuesday message to shareholders from CEO Michelle Miller, who talked about the near-term outlook for BIT as it nears the final stage of three Phase 2 clinical trials for HIV‐1 and COVID‐19.
Biotron is developing a batch of new anti-viral therapies which potentially have broad applications.

 

[Dona Ferentes]

too fast, df. ...

.

 

[Boggo]

Positive news really pushing it up today (Disc - I do hold).

 

[frugal.rock]

Up a bit more than a bit.
What a bit, I don't hold.

 

[Country Lad]

I have been watching this for a bit. It looked a bit promising early November when it jumped more than a bit to 11 cents without even a bit of news. Thought I should watch it a bit longer and it went down more than a bit over the next couple of weeks.

Then up more than a bit and to a bit of a break on 10 Nov. Momentum dropped a bit next day so watched price fall more than a bit over the next 7 days. Happy I could have bit the bullet but didn’t.

Address to AGM today emphasised that more than a bit of patience is required.

"With so much depending on the outcomes – and by that I mean medically and commercially – we will do whatever is required to ensure that the integrity of the process is protected. For now, patience – in short supply, I know – is required of us all."

So it went up more than a bit today (15%) on a bit of optimism but no real news. Problem with these small biotechs doing trials, not many make breakthroughs.

A break above 13 will have me real bit interested.

 

[frugal.rock]